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ABSTRACT
The Screening for Osteoporosis in Older Women for the Prevention of Fracture (SCOOP) study was a community-based screening
intervention in women aged 70 to 85 years in the United Kingdom. In the screening arm, licensed osteoporosis treatments were
recommended in women identiﬁed to be at high risk of hip fracture using the FRAX risk assessment tool (including bone mineral
densitymeasurement). In the control arm, standard carewas provided. Screening led to a 28% reduction in hip fractures over 5 years.
In this planned post hoc analysis, we wished to examine for interactions between screening effectiveness on fracture outcome (any,
osteoporotic, and hip fractures) on the one hand and baseline FRAX 10-year probability of hip fracture on the other. All analyseswere
conducted on an intention-to-treat basis, based on the group to which women were randomized, irrespective of whether screening
was completed. Of 12,483 eligible participants, 6233 women were randomized to screening, with treatment recommended in 898
(14.4%). No evidence of an effect or interaction was observed for the outcomes of any fracture or osteoporotic fracture. In the
screening arm, 54 fewer hip fractures were observed than in the control arm (164 versus 218, 2.6% versus 3.5%), and commensurate
with treatment being targeted to those at highest hip fracture risk, the effect on hip fracture increased with baseline FRAX hip
fracture probability (p¼ 0.021 for interaction); for example, at the 10th percentile of baseline FRAX hip probability (2.6%), there was
no evidence that hip fractures were reduced (hazard ratio [HR]¼ 0.93; 95% conﬁdence interval [CI] 0.71 to 1.23), but at the 90th
percentile (16.6%), there was a 33% reduction (HR¼ 0.67; 95% CI 0.53 to 0.84). Prior fracture and parental history of hip fracture
positively inﬂuenced screening effectiveness on hip fracture risk. We conclude that women at high risk of hip fracture based on FRAX
probability are responsive to appropriate osteoporosis management. © 2018 American Society for Bone and Mineral Research.
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Introduction
Over the last few years, treatment based on the absolute riskof fracture has been incorporated into many national and
international guidelines, given the availability of validated
fracture risk assessment tools such as FRAX, launched in
2008.(1,2) For example, in the United Kingdom, speciﬁc age-
dependent intervention thresholds based on 10-year probability
of fracture are advocated by the National Osteoporosis Guideline
Group in their recent NICE-accredited guidance.(3) A cornerstone
of the clinical utility of fracture risk tools is that the risk identiﬁed
shouldbe reversible bybone-targeted therapies, and a number of
post hoc analysesof phase 3 clinical trials havedemonstrated that
this is the case for risk identiﬁed by FRAX.(4–11) Very recently, the
ﬁrst study that prospectively screened patients using FRAX
probabilities to assess fracture risk (the Screening for Osteoporo-
sis in OlderWomen for the Prevention of Fracture [SCOOP] study)
has been published.(12) This UKmulticenter study, largely primary
care based, assessed the effectiveness of a FRAX-based,
community screening program in women aged 70 to 85 years,
with treatment targeted at women at high risk of hip fracture,
compared with a control group receiving standard clinical care.
The approach appears to be acceptable to both patients and
GPs.(13) During 5 years of follow-up, prescriptions for anti-
osteoporosis medications were more frequent, and hip fracture
incidence lower, in the screening intervention arm compared
with the control arm (Table 1). Anti-osteoporosis medications
were particularly frequently prescribed in those intervention
participants classiﬁed as high fracture risk, and so we hypothe-
sized that the effect of screening to reduce hip fractureswould be
greatest in women with higher baseline FRAX probability, with a
consequent interaction between baseline FRAX hip fracture
probability and screening effectiveness.
Materials and Methods
The SCOOP clinical study was a pragmatic, unblinded, two-
group, parallel, randomized controlled trial to assess the
effectiveness and cost-effectiveness of screening to prevent
fractures in older women; the design and results have been
published previously.(12,14) In brief, women aged 70 to 85 years,
not already on osteoporosis medications but suitable to
participate, were approached through primary-care lists in
and around seven regions of England.Written, informed consent
was obtained from all agreeing to participate, and they
completed a self-ﬁlled questionnaire capturing the FRAX risk
factors before being randomized to the intervention (screening)
or control arm. Baseline data comprised age, sex, height, and
weight for body mass index (BMI) calculation and dichotomized
risk variables including a prior fragility fracture since the age of
50 years, parental history of hip fracture, current tobacco
smoking, any long-term use of oral glucocorticoids, rheumatoid
arthritis, other causes of secondary osteoporosis, and daily
alcohol consumption of3 units daily. If the respondent did not
know the answer to an individual question, a negative response
was assumed.
In the screening arm, the baseline risk factor questionnaire
was used to calculate the 10-year probability of hip fracture
using the FRAX risk algorithm. Women deemed at moderate to
high risk of hip fracturewere invited to undergo a dual-energy X-
ray absorptiometry (DXA) measurement of femoral neck bone
mineral density (BMD) measurement and the 10-year hip
fracture probability was recalculated with inclusion of BMD.
The ﬁnal risk category (low or high) was communicated to the
participant and family doctor by letter; participants remaining at
high risk after incorporation of BMD into FRAX were advised to
make an appointment with their family doctor to discuss
treatment options.
In the control arm, apart from a letter to the general
practitioner informing them of their patient participating in the
study, no additional information was provided and they
received usual care. The baseline 10-year FRAX probabilities,
without the inclusion of BMD, were calculated at the end of the
trial for comparative purposes only.
During 5 years of follow-up, exposure to osteoporosis
treatment was higher in the screening arm with around 24%
of the screening arm participants receiving at least one
prescription for anti-osteoporosis medication compared with
16% of the control arm. The difference reﬂected a high uptake of
treatment in the high-risk group within the screening arm with
703 women (78.3% of the high-risk group) having received at
least one prescription of anti-osteoporosis medication within
6 months of randomization.
Fracture outcomes
Only veriﬁed fractures at any anatomical site within the 5-year
follow-up period were included as outcomes. In brief, we
captured self-reported fractures as well as searching routine
Hospital Episode Statistics data, comprising information on
hospital inpatient stays and emergency department attendance,
together with primary-care records to identify fractures in any of
the study participants from the point of randomization until the
end of follow-up. Only independently conﬁrmed fractures were
included. Incident osteoporosis-related fractures were deﬁned
as those excluding the hands, feet, nose, skull, or cervical
vertebrae. Hip fractures were deﬁned as veriﬁed fractures with a
speciﬁc description of “neck of femur” or “proximal femur.”
Statistical analysis
Because BMD measurements were not undertaken in all
participants, the FRAX 10-year hip fracture probability calculated
without BMD was used in the analyses because this was
Table 1. Fracture and Mortality Outcomes in the SCOOP Trial of Screening in Women Aged 70 to 85 Years in England(12)
Outcomes Control (n¼ 6250) Screening (n¼ 6233) Hazard ratioa p Value
OP-related fractures 852 (13.6%) 805 (12.9%) 0.94 (0.85–1.03) 0.178
Any clinical fracture 1002 (16.0) 951 (15.3) 0.94 (0.86–1.03) 0.18
Hip fractures 218 (3.5%) 164 (2.6%) 0.72 (0.59–0.89) 0.002
Deaths 525 (8.4%) 550 (8.8%) 1.05 (0.93–1.19) 0.436
OP¼ osteoporosis (excludes fractures of the hands, feet, nose, skull, or cervical vertebrae).
aAdjusted for recruiting region, baseline FRAX probability, and falls.
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available in both the control and intervention groups. A Poisson
model was used to study the relationship between age, the time
since baseline, invitation for screening, and FRAX 10-year
probability of hip fracture on the one hand, and on the other
hand, the risk of any fracture, osteoporotic fracture or hip
fracture with only one fracture being counted per patient during
follow-up (expressed as person-years). A reduction in hip
fracture risk that showed no interaction, with a ﬂat reduction
in risk across the range of baseline risk, would have suggested
that factors other than treatment could have explained the
observed effect.
All analyses were conducted on an intention-to-treat basis
with participants analyzed according to the group to which they
were randomized, irrespective of whether screening was
completed. The hazard function was assumed to be exp-
(b0þb1  current time from baselineþb2  current ageþb3 
10-year probabilityþb4  screeningþb5  10-year probability 
screening). The beta coefﬁcients reﬂect the importance of the
variables as in a logistic model, and bx¼ 0 denotes that the
corresponding variable does not contribute to fracture risk. The
variable “10-year probability  screening” tested for an interac-
tion between screening effectiveness and baseline 10-year
probability, handled as a continuous variable, by determining if
b5< >0. Hazard ratios (HR) for screening effect and 95%
conﬁdence intervals (95% CI) were computed as a continuous
variable. For presentation, hazard ratios were shown at the 10th,
25th, 50th, 75th, and 90th percentile of fracture probability.
Further analyses explored the interaction between effectiveness
and individual clinical risk factors within FRAX to determine the
drivers of any potential interaction. A similar analysis was
conducted for any fracture and all incident osteoporotic
fractures. An exploratory analysis used the 10-year probability
of major osteoporotic fracture instead of hip fracture as the
baseline risk.
Results
Baseline characteristics
A total of 12,483 women were randomized, with 6250 assigned
to the control group and 6233 to the screening arm. The two
groupswere very similar at baseline (Table 2), with amean age of
75 years and mean BMI just under 27 kg/m2 in both groups. The
completion rates for the risk factors in the questionnaire were all
above 90%, ranging from 92.6% for parental history of hip
fracture to 99.9% for current smoking, and were similar in the
screening and control arms. The prevalence of FRAX risk factors
in the control group ranged from 3.6% for average alcohol
intake above 3 units per day to 23.4% for prior fracture, with very
similar rates in the screening arm. After DXA measurement of
femoral neck BMD in 2817 women considered to be at
moderate/high risk in the screening arm and recalculation of
their FRAX hip fracture probabilities, 898 (14.4% of the screening
arm) were identiﬁed to be at high risk and treatment
recommended via their general practitioner. As expected, given
the risk factors included in FRAX, these women tended to be
older, have lower BMI, and a higher prevalence of risk factors
than those in the control arm (Table 2). The mean FRAX 10-year
probability of hip fracture, calculated without BMD, was more
than twofold higher in those identiﬁed at high risk compared
with the control group.
Baseline FRAX hip fracture probability and observed
incidence of fractures
Over 5 years of follow-up, 3.5%, 11.6%, and 13.6% of the control
arm sustained a new hip fracture, a new major osteoporotic
fracture, or any new osteoporotic fracture, respectively. There
was evidence of an increase in the observed incidence of hip and
osteoporotic fractures in the control arm of the study (Fig. 1)
across the range of baseline FRAX hip fracture probability. For
example, the observed incidence of hip fracture was 6.5-fold
higher in the highest quintile of baseline risk compared with the
lowest quintile of risk. The incidence of osteoporotic fractures
also increased in a stepwise fashion across the quintiles of risk,
but the increase was less marked than that found in hip
fractures, with only a 2.3-fold increase from lowest to highest
quintile.
Effectiveness and relationship to FRAX
In Table 3, the effects of screening on various categories of
fracture outcomes are shown, according to the baseline FRAX
10-year probability of a hip fracture. The latter was entered as a
continuous variable in the model, but for illustrative purposes,
the table shows the effect at various values of baseline
probability. Conﬁdence estimates for the hazard ratio crossed
Table 2. Baseline Characteristics of the Control and Screening Arms, Including Details of Those Identiﬁed at High Risk Within the
Screening Group
Control (n¼ 6250) Screening (n¼ 6233) Screened high risk (n¼ 898)
Age (years), mean (SD) 75.5 (4.1) 75.4 (4.2) 77.2 (4.4)
Body mass index, mean (SD) 26.7 (4.8) 26.7 (4.7) 24.4 (4.1)
Self-reported prevalence, n (%)
Fracture since age 50 years 1463 (23.4%) 1399 (22.4%) 409 (46.0%)
Parental hip fracture 577 (9.2%) 585 (9.4%) 354 (41.6%)
Smoking 290 (4.6%) 290 (4.7%) 86 (9.6%)
Alcohol3 units/d 225 (3.6%) 219 (3.5%) 60 (6.7%)
Glucocorticoid use 312 (5.0%) 316 (5.1%) 113 (13.3%)
Rheumatoid arthritis 410 (6.6%) 426 (6.8%) 79 (9.3%)
Secondary causes of OP 1408 (22.5%) 1483 (23.8%) 267 (29.7%)
FRAX 10-year hip fracture probability
(without BMD); mean (SD)
8.5% (7.3%) 8.5% (7.4%) 17.9% (10.9%)
OP¼ osteoporosis/osteoporotic.
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unity at all probabilities for any fracture and osteoporotic
fractures, with no evidence of an interaction between
effectiveness and baseline FRAX hip fracture probability.
In contrast, the hazard ratio showed an interaction with
baseline FRAX hip fracture probability for the outcome of hip
fracture (p¼ 0.021), and the upper conﬁdence intervals were
below unity at higher baseline risk (Table 3). The interaction
between screening effect and fracture probability for the
outcome of hip fracture is shown in Fig. 2. At the median value
of baseline hip fracture probability in the whole study
population (6.3%), invitation for screening was associated
with a 15% reduction in hip fracture risk albeit with a 95% CI
that included the null. At the 90th centile of the whole
population risk (16.8%), there was a larger 33% reduction with a
95% CI that excluded the null, and at the 90th centile of baseline
risk in the high-risk population (32%), the reduction was even
higher at 53% (95% CI 26% to 70%) (Fig. 2).
Components of screening effect
In the context of evidence for an interaction between fracture
probability and screening, we explored the potential drivers of
the screening effect by examining the effect on hip fracture risk
as a function of each variable within FRAX. For the continuous
variables of age and BMI, there was no evidence of an interaction
with screening. For example, at a BMI of 21 kg/m2, screening
reduced hip fracture risk by 24% (HR¼ 0.76; 95% CI 0.57 to 1.01),
with a similar reduction at a BMI of 33 kg/m2 (HR¼ 0.73; 95% CI
0.47 to 1.14). BMD could not be included in this analysis because
of its absence in the vast majority of women in the control arm.
The interaction between screening effectiveness on hip
fracture risk and the dichotomous variables within FRAX are
shown in Table 4. For both prior fracture and parental history of
hip fracture, there was evidence of an interaction, with greater
effect on hip fracture reduction in those with the risk factor
present. In contrast, an interaction was observed for prevalent
smokingwhereby non-smokers appeared to achieve the beneﬁt,
whereas current smokers did not.
Discussion
The SCOOP study is the ﬁrst prospective, randomized study to
utilize the absolute risk of fracture, determined as the FRAX
10-year probability of hip fracture, as the means to target
intervention to reduce fracture risk. It has demonstrated the
effectiveness of a community-based, screening program in
women aged 70 to 85 years to reduce hip fractures, showing an
average 28% reduction in incidence.(12) Because intervention
was targeted only at those women with high risk of hip fracture,
we hypothesized that there would be an interaction between
baseline risk and screening effectiveness, and the present
analysis conﬁrms this to be the case. In individuals at very high
risk of hip fracture, the estimated reduction in hip fracture risk
was more than 50%.
The study design of the SCOOP study has strengths and
limitations. The pragmatic design, in which a novel strategy was
directly compared with existing practice, allowed assessment of
the effectiveness of the screening pathway in reducing hip
fracture risk.(12) The main limitation is the lack of BMD
measurements in some of the screening arm and the vast
majority of the control arm, impairing the ability to undertake
traditional post hoc subgroup analyses. However, the use of
FRAX probabilities as a continuous variable has been used to
investigate interactions with treatment effects in a number of
previous analyses,(4–11) and it is particularly apt for use in the
current study where the exposure to treatment varied by the
baseline risk. The greater reduction in hip fracture risk at higher
baseline risk suggests that treatment rather than other factors
explained the observed effect.
Exploratory examination of individual FRAX risk factors shows
that the screening effectiveness was particularly inﬂuenced by
the presence of the twomost prevalent clinical risk factors in the
high-risk group, namely prior fracture and parental history of hip
fracture. For both risk factors, the effect of screening was greater
in those with the risk factor present, raising questions about the
potential underlying mechanism. The most obvious and most
Fig. 1. Observed incidence of osteoporotic and hip fractures during
follow-up in the control arm of the SCOOP study, within quintiles of
baseline FRAX hip probability.
Table 3. Hazard Ratio (95% Conﬁdence Interval) Between Screening and Control Arms for any Fracture, Osteoporotic Fracture, and Hip
Fracture at Different Values of FRAX 10-Year Probability (%) of a Hip Fracture Calculated Without Bone Mineral Density
Centile FRAX probability Any fracture Osteoporotic fracture Hip fracture
10th 2.6 0.96 (0.86–1.08) 0.97 (0.85–1.09) 0.93 (0.71–1.23)
25th 3.8 0.96 (0.86–1.07) 0.96 (0.86–1.08) 0.91 (0.70–1.17)
50th 6.3 0.96 (0.87–1.05) 0.96 (0.86–1.06) 0.85 (0.68–1.08)
75th 10.5 0.95 (0.87–1.04) 0.95 (0.86–1.04) 0.77 (0.63–0.95)
90th 16.8 0.94 (0.84–1.05) 0.93 (0.83–1.05) 0.67 (0.53–0.84)
p Value >0.30 >0.30 0.021
The p value is for the interaction between screening and the outcome.
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likely mechanism, of course, is that these two factors drove the
increased exposure to treatment in the intervention arm. The
well-documented association between prior fracture and lower
BMD might suggest that the greater effect was additionally
mediated by the presence of a lower or osteoporotic BMD, but
the evidence base for that is questionable for most antiresorp-
tivemedications.(15) The effective reduction in hip fracture risk in
these 70- to 85-year-old women with prior fracture is, however,
supportive of the many international and national guidelines,
including those in the UK, which state that all such women
should be strongly considered for osteoporosis therapy, without
necessarily measuring BMD, recently recognized as an unmet
need in closing the osteoporosis treatment gap.(1,3,16,17) There is
certainly little evidence for a strong relationship between a
parental history of hip fracture and BMD; indeed, meta-analysis
shows that the effect of parental history on fracture risk is almost
completely independent of BMD.(18) A further potential
explanation is that both factorsmay have inﬂuenced persistence
aswell as uptake of osteoporosis therapies, a hypothesis that will
be explored in a subsequent analysis of the SCOOP study.
Certainly, the study participants represented motivated
volunteers with a higher level of education, more fracture risk
factors but less frequent smoking exposure than non-
participants.(12)
The results of the SCOOP study have potential impacts on
future health care policy, including the implementation of a
screening strategy for fracture prevention. Indeed, a screening
approach was recommended by NICE in 2012, when it proposed
that all women aged 65 years or older and men aged 75 years or
older should have a fracture risk assessment using the FRAX or
QFracture tools.(19) In contrast to FRAX, the risk identiﬁed by
the QFracture tool has not been examined for reversibility,
intervention thresholds have not been deﬁned, and QFracture
does not permit the incorporation of BMD values into the risk
assessment. The SCOOP study readily demonstrates the
reversibility of high risk identiﬁed by FRAX; interestingly, the
intervention thresholds used in SCOOP, deﬁned before the
launch of the ﬁrst NOGG guidance in 2008, ranged from a FRAX
10-year probability of hip fracture from 5.24% in 70- to 75-year-
olds to 8.99% in 85-year-olds. In the recently updated NOGG
guidance, treatment is recommended in patients aged 70 years
or older with a 10-yearmajor osteoporotic fracture probability of
at least 20% or a hip fracture probability of at least 5%,(3)
thresholds that are associated with very acceptable cost-
effectiveness as concluded by the recent NICE HTA on oral
and intravenous bisphosphonates.(20)
Preliminary health economic analyses of the SCOOP study
indicate that the cost per preventedhip fracture is less than £8000
and that the cost per quality-adjusted life year (QALY) gained,
estimated under a number of different scenarios, is less than
£20,000.(12) If one estimates that had screening been applied to
the whole SCOOP study, then approximately 108 hip fractures
would have been prevented. The original target population for
the study comprised 52,033 women aged 70 to 85 years,
suggesting that if the SCOOP strategy was applied across the
whole population of 70- to 85-year-old women in the UK,
estimated at 3.7million (2016, mid-year estimate),(21) then almost
8000 hip fractures could be prevented each year; this could be
further enhanced by mechanisms that extended the strategy to
the two-thirds of eligible women who did not participate in the
screening study, as well as combining osteoporosis treatment
with falls prevention in eligible individuals.
In conclusion, the analysis demonstrates an interaction
between baseline FRAX hip fracture probability and a subse-
quent reduction in hip fracture incidence in those at higher risk
targeted for appropriate treatment. Treatment success appears
to have been driven by factors that might inﬂuence treatment
Fig. 2. Impact of screening on hip fracture compared with control arm,
expressed as hazard ratio, across range of FRAX 10-year hip fracture
probabilities at baseline, calculated without BMD. There was evidence of
an interaction of effectiveness with baseline probability (p¼ 0.021). The
symbols indicate the range of baseline probabilities in the whole study
population (closed symbols) and in the high-risk group identiﬁed by
screening (open symbols).
Table 4.Hazard Ratio Between Study Arms (Screening Versus Control) for Hip Fractures in ThoseWith andWithout the Presence of a Risk
Factor at Baseline
Hazard ratio (95% confidence interval)
FRAX variable Absent Present p Value
Previous fracture 0.87 (0.68–1.12) 0.55 (0.38–0.79) 0.040
Parental hip fracture 0.79 (0.63–0.99) 0.27 (0.13–0.56) 0.006
Glucocorticoid use 0.76 (0.61–0.94) 0.75 (0.28–2.01) >0.30
Smoking 0.72 (0.58–0.88) 1.93 (0.78–4.79) 0.037
Alcohol 0.76 (0.62–0.94) 0.68 (0.24–1.92) >0.30
Rheumatoid arthritis 0.72 (0.58–0.90) 0.83 (0.40–1.70) >0.30
Secondary osteoporosis 0.77 (0.61–0.97 0.71 (0.47–1.08) >0.30
The p value represents signiﬁcance for the interaction between presence and absence of the risk factor.
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adherence, a hypothesis that can be investigated in subsequent
analyses. Future studies should examine how this FRAX-based
approach can be made available to, or accessible by, the wider
community to achieve greater reductions in the number of hip
fractures in the UK and elsewhere.
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